FDA approves drug to treat smallpox

Created on 2021-11-17T23:42:43-06:00

Return to the Index

This card pertains to a resource available on the internet.

This card can also be read via Gemini.

FDA, 6/4/2021.

The U.S. Food and Drug Administration today approved Tembexa (brincidofovir) to treat smallpox.
Authorization granted without human testing.
Tembexa received priority review, fast track and orphan drug designations.
Tembexa was developed in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). FDA granted approval of Tembexa to Chimerix Inc.